Literature DB >> 2189885

Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus.

B Gumbiner1, K S Polonsky, W F Beltz, K Griver, P Wallace, G Brechtel, R R Henry.   

Abstract

Impairment in pancreatic production of insulin, a cardinal feature of noninsulin dependent diabetes mellitus (NIDDM), was quantified and the kinetics of insulin secretion characterized in six obese individuals with NIDDM before and after weight loss (18.0 +/- 3.0 kg, mean +/- SEM) using a validated mathematical model that employs C-peptide as a marker of the in vivo rate of insulin secretion. The metabolic clearance of C-peptide, assessed by decay analysis after bolus injection of biosynthetic human C-peptide, was not changed by weight loss (0.143 +/- 0.009 L/min.m2 vs. 0.137 +/- 0.010 L/min.m2). Kinetic parameters from each individual's decay curve before and after weight loss were used to derive accurate rates of secretion during the basal (postabsorptive) state, an oral glucose tolerance test and two hyperglycemic clamps. Basal rates of insulin secretion declined 20 +/- 5 pmol/min.m2 (96 +/- 15 to 76 +/- 15 pmol/min.m2, P less than 0.05) concomitant with decreases of 6.9 +/- 0.9 mmol/L in fasting serum glucose (13.7 +/- 1.0 to 6.8 +/- 0.7 mmol/L, P less than 0.05), 60 +/- 14 pmol/L in serum insulin (134 +/- 30 to 74 +/- 15 pmol/L, P less than 0.05), and 0.15 +/- 0.03 pmol/ml in plasma C-peptide (0.67 +/- 0.11 to 0.52 +/- 0.08 pmol/ml, P less than 0.05) concentrations. As expected, weight loss resulted in improved glucose tolerance as measured by the glycemic profiles during the oral glucose tolerance test (P less than 0.05 analysis of variance). The insulin secretory response before weight loss showed a markedly reduced ability to respond appropriately to an increase in the ambient serum glucose. After weight loss, the pancreatic response was more dynamic (P less than 0.05, analysis of variance) and parralleled the moment-to-moment changes in glycemia. Insulin production above basal doubled (11.2 +/- 3.2 to 24.5 +/- 5.8 nmol/6h.m2, P less than 0.05) and peak rates of insulin secretion above basal tripled (55 +/- 16 to 157 +/- 32 pmol/min/m2, P less than 0.05). To assess the beta-cell response to glucose per se and the changes associated with weight reduction, two hyperglycemic clamps were performed at steady state glucose levels in the range characteristic of individuals with severe NIDDM. At a fixed glycemia of 20 mmol/L, average rates of insulin secretion increased almost 2-fold with treatment (161 +/- 41 to 277 +/- 60 pmol/min.m2, P less than 0.05). At an increment of 6 mmol/L glucose above prevailing fasting glucose levels, the average rate of insulin secretion increased 53% (120 +/- 21 to 183 +/- 39 pmol/min.m2, P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189885     DOI: 10.1210/jcem-70-6-1594

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Predictors of short-term diabetes remission after laparoscopic Roux-en-Y gastric bypass.

Authors:  Gianluca Iacobellis; Chengyu Xu; Rafael E Campo; Nestor F De La Cruz-Munoz
Journal:  Obes Surg       Date:  2015-05       Impact factor: 4.129

Review 2.  Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?

Authors:  Mousumi Bose; Blanca Oliván; Julio Teixeira; F Xavier Pi-Sunyer; Blandine Laferrère
Journal:  Obes Surg       Date:  2008-09-27       Impact factor: 4.129

3.  Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide.

Authors:  Thomas P J Solomon; Jacob M Haus; Karen R Kelly; Michael Rocco; Sangeeta R Kashyap; John P Kirwan
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

4.  Short cycles of very low calorie diet in the therapy of obese type II diabetes mellitus.

Authors:  C M Rotella; B Cresci; E Mannucci; S M Rizzello; G Colzi; G Galli; S Giannini; G Messeri; F Piani; R Vannini
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

5.  Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance.

Authors:  J Kusari; K A Kenner; K I Suh; D E Hill; R R Henry
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

6.  Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes.

Authors:  Blandine Laferrère; Stanley Heshka; Krystle Wang; Yasmin Khan; James McGinty; Julio Teixeira; Allison B Hart; Blanca Olivan
Journal:  Diabetes Care       Date:  2007-04-06       Impact factor: 19.112

7.  C-Peptide versus insulin: relationships with risk biomarkers of cardiovascular disease in metabolic syndrome in young arab females.

Authors:  A Abdullah; H Hasan; V Raigangar; W Bani-Issa
Journal:  Int J Endocrinol       Date:  2012-08-01       Impact factor: 3.257

8.  Incretin-based therapy and the quest for sustained improvements in β-cell health.

Authors:  Daniel J Drucker
Journal:  Diabetes Care       Date:  2011-09       Impact factor: 19.112

9.  Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Authors:  Julio Rosenstock; Naresh Aggarwal; David Polidori; Yue Zhao; Deborah Arbit; Keith Usiskin; George Capuano; William Canovatchel
Journal:  Diabetes Care       Date:  2012-04-09       Impact factor: 19.112

Review 10.  Assessment of pancreatic β-cell function: review of methods and clinical applications.

Authors:  Eugenio Cersosimo; Carolina Solis-Herrera; Michael E Trautmann; Jaret Malloy; Curtis L Triplitt
Journal:  Curr Diabetes Rev       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.